MedTrace Logo

Endocalyx in Treatment Resistent Hypertension

NCT06940011 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-04-23

No results posted yet for this study

Summary

The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.

Conditions

  • Treatment Resistant Hypertension

Interventions

DIETARY_SUPPLEMENT

Endocalyx Pro

4 capsules once daily OR 2 capsules twice daily

OTHER

Placebo

4 capsules once daily OR 2 capsules twice daily

Sponsors & Collaborators

  • Dutch Heart Foundation

    collaborator OTHER

  • Dutch Kidney Foundation

    collaborator OTHER

  • Microvascular Health Solutions LLC

    collaborator UNKNOWN

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-21
Primary Completion
2027-12-01
Completion
2028-01-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940011 on ClinicalTrials.gov